Experienced in Pemphigus Vulgaris

Hsien-yi Y. Chiu

National Taiwan University Hospital Hsin Chu Branch
Hsinchu, TNQ, TW 
Experienced in Pemphigus Vulgaris
National Taiwan University Hospital Hsin Chu Branch
Hsinchu, TNQ, TW 
OverviewLocationsClinical Research

Overview

Hsien-yi Chiu practices in Hsinchu, Taiwan. Chiu is rated as an Experienced expert by MediFind in the treatment of Pemphigus Vulgaris. Their top areas of expertise are Psoriasis, Psoriatic Arthritis, Necrosis, and Scleredema.

Their clinical research consists of co-authoring 98 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Pemphigus Vulgaris.

Locations

National Taiwan University Hospital Hsin Chu Branch
Hsinchu, TNQ, Taiwan
Other Locations
1, Jen Ai Rd, 100, TPQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Enrollment Status: Completed
Publish Date: September 25, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

98 Total Publications

Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: a 15-year multicenter cohort study.
Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: a 15-year multicenter cohort study.
Journal: Journal of the American Academy of Dermatology
Published: June 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chiu's expertise for a condition
ConditionClose
    View All 36 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile